Biotech company Acuitas Therapeutics and Germany-based CureVac have settled Acuitas' lawsuit demanding credit for inventions ...

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants ...

Vertex Pharmaceuticals Inc‘s (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, ...

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of ...

The Fund seeks capital appreciation. The Fund normally invests at least 80% of its net assets in publicly-traded domestic micro-cap companies. Micro-cap companies are those with market ...

Beyond a doubt, Vancouver-based Acuitas Therapeutics, Inc. punches above its weight. It is the global leader in developing lipid nanoparticle (LNP) delivery technology for nucleic acid ...

Kaiser Permanente Entity Reports Breach Of Data For 13 Million: Kaiser Permanente, the Oakland-based health care conglomerate, is warning millions of customers that one of its divisions may have ...

Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for ...

On October 31, 2023, the Company and Acuitas Capital entered into a Fifth Amendment to the Master Note Purchase Agreement, as amended (the "Fifth Amendment"), which, among other things ...

In the U.S., a magistrate judge recently granted a motion by Acuitas Therapeutics to intervene, sever and stay the CureVac’s U.S. litigation against Pfizer/BioNTech. The motion is based on co ...

On October 31, 2023, the Company and Acuitas Capital entered into a Fifth Amendment to the Master Note Purchase Agreement, as ...